Century Therapeutics, Inc.
Century Therapeutics, Inc. (IPSC) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · IPSC · as of Jun 9, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
14
12 Months
Buy/Sell ratio
0.21
Buy/Sell (by trades)
Overall sentiment
Century Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
IPSC insider buying and selling by quarter
IPSC insider selling · IPSC insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · IPSC ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
IPSC executive sell shares · IPSC board member insider trading · IPSC insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 15, 2026 | Pfeiffenberger Brent President and CEO · Director | Other | 31,172 | $73K | Form 4 |
| May 4, 2026 | Carr Douglas SVP Finance & Operations | Sale | 264 | $618 | Form 4 |
| Apr 1, 2026 | Cowan Chad Chief Scientific Officer | Other | 1,365 | $3K | Form 4 |
| Mar 12, 2026 | Carr Douglas SVP Finance & Operations | Sale | 7,043 | $18K | Form 4 |
| Mar 12, 2026 | Russotti Gregory See Remarks | Sale | 10,076 | $26K | Form 4 |
| Mar 11, 2026 | Pfeiffenberger Brent President and CEO · Director | Other | 55,397 | $151K | Form 4 |
| Mar 11, 2026 | Cowan Chad Chief Scientific Officer | Other | 1,431 | $4K | Form 4 |
| Mar 9, 2026 | Russotti Gregory See Remarks | Sale | 479 | $1K | Form 4 |
| Mar 6, 2026 | Pfeiffenberger Brent President and CEO · Director | Other | 463 | $1K | Form 4 |
| Feb 13, 2026 | Pfeiffenberger Brent President and CEO · Director | Other | 31,172 | $55K | Form 4 |
| Feb 3, 2026 | Carr Douglas SVP Finance & Operations | Sale | 323 | $589 | Form 4 |
| Feb 2, 2026 | Pfeiffenberger Brent President and CEO · Director | Award | 475,000 | — | Form 4 |
| Feb 2, 2026 | Russotti Gregory See Remarks | Award | 135,000 | — | Form 4 |
| Feb 2, 2026 | Cowan Chad Chief Scientific Officer | Award | 135,000 | — | Form 4 |
| Feb 2, 2026 | Carr Douglas SVP Finance & Operations | Award | 110,000 | — | Form 4 |
| Jan 2, 2026 | Cowan Chad Chief Scientific Officer | Other | 1,611 | $2K | Form 4 |
| Dec 22, 2025 | Cowan Chad Chief Scientific Officer | Purchase | 58,060 | $49K | Form 4 |
| Dec 12, 2025 | Pfeiffenberger Brent President and CEO · Director | Purchase | 52,000 | $30K | Form 4 |
| Dec 10, 2025 | Pfeiffenberger Brent President and CEO · Director | Other | 463 | $244 | Form 4 |
| Dec 8, 2025 | Carr Douglas SVP Finance & Operations | Sale | 257 | $137 | Form 4 |
| Dec 8, 2025 | Russotti Gregory See Remarks | Sale | 526 | $280 | Form 4 |
| Nov 20, 2025 | Cowan Chad Chief Scientific Officer | Sale | 5,462 | $3K | Form 4 |
| Nov 19, 2025 | Pfeiffenberger Brent President and CEO · Director | Purchase | 35,000 | $17K | Form 4 |
| Nov 17, 2025 | Pfeiffenberger Brent President and CEO · Director | Sale | 32,456 | $15K | Form 4 |
| Nov 3, 2025 | Carr Douglas SVP Finance & Operations | Sale | 292 | $171 | Form 4 |
Pfeiffenberger Brent
President and CEO · Director
Date
May 15
Shares
31,172
Price
$2.34
Value
$73K
Carr Douglas
SVP Finance & Operations
Date
Mar 12
Shares
7,043
Price
$2.55
Value
$18K
Pfeiffenberger Brent
President and CEO · Director
Date
Mar 11
Shares
55,397
Price
$2.73
Value
$151K
Cowan Chad
Chief Scientific Officer
Date
Mar 11
Shares
1,431
Price
$2.73
Value
$4K
Pfeiffenberger Brent
President and CEO · Director
Date
Mar 6
Shares
463
Price
$2.56
Value
$1K
Pfeiffenberger Brent
President and CEO · Director
Date
Feb 13
Shares
31,172
Price
$1.75
Value
$55K
Pfeiffenberger Brent
President and CEO · Director
Date
Feb 2
Shares
475,000
Price
—
Value
—
Cowan Chad
Chief Scientific Officer
Date
Dec 22
Shares
58,060
Price
$0.85
Value
$49K
Pfeiffenberger Brent
President and CEO · Director
Date
Dec 12
Shares
52,000
Price
$0.58
Value
$30K
Pfeiffenberger Brent
President and CEO · Director
Date
Dec 10
Shares
463
Price
$0.53
Value
$244
Pfeiffenberger Brent
President and CEO · Director
Date
Nov 19
Shares
35,000
Price
$0.50
Value
$17K
Pfeiffenberger Brent
President and CEO · Director
Date
Nov 17
Shares
32,456
Price
$0.45
Value
$15K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About IPSC insider trading
IPSC insider trades
Century Therapeutics, Inc. (IPSC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Pfeiffenberger Brent (President and CEO · Director), Carr Douglas (SVP Finance & Operations), Cowan Chad (Chief Scientific Officer). Over the past 12 months, 4 insiders have filed transactions with the SEC. IPSC insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Century Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
IPSC insider trading · 5 questionsThe insiders of Century Therapeutics, Inc. (IPSC) include executives and directors such as Pfeiffenberger Brent (President and CEO · Director), Carr Douglas (SVP Finance & Operations), Cowan Chad (Chief Scientific Officer), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026